Helping Pharmaceutical Companies Develop More Effective Prostate Cancer Treatments

Aureon Laboratories Clinical Research Services

Developing effective prostate cancer treatments is an incredibly challenging and costly endeavor, and is often met with inadequate response rates in terms of overall survival and / or progression free survival. The use of molecular biomarkers in recent years has shown promise in predicting therapeutic responders for oncology clinical development.

Aureon Laboratories is ideally suited to partner with bio-pharmaceutical companies undertaking these challenges and has extended access to our Systems Pathology platform to assist in the in situ validation of clinically meaningful biomarkers, and the construction of predictive and prognostic models for patient stratification. Our focus includes the following solid tumor types: Prostate, NSCLC, Breast, Bladder, Colon.

While many bio-pharmaceutical companies have an active program in place for tissue-based biomarker analysis, Aureon offers the following distinctions:

• Development of custom, multiplexed immunofluorescence assays for protein biomarker analysis
• In situ, object-based morphometric quantitation of tissue histology and protein biomarkers takes into account tumor heterogeneity providing greater biological content and context
• Validation pipeline to identify which histological, molecular, or clinical phenotypes have clinical relevance
• Multivariate analysis and association to clinical endpoints of interest
• A CLIA / GLP laboratory that focuses on developing and performing tests for the general public

Bio-pharmaceutical companies can now access Aureon’s Systems Pathology platform via our clinical research services program in order to achieve completion of biomarker related projects faster, with more informative data, and less cost than traditional in-house methods.